-
公开(公告)号：KR1020130109425A
公开(公告)日：2013-10-08
申请号：KR1020120031154
申请日：2012-03-27
Applicant: 일양약품주식회사
IPC: A61K31/505 , A61K31/417 , A61K9/16 , A61K9/20
CPC classification number: A61K31/506 , A61K9/2009 , A61K9/485
Abstract: PURPOSE: A pharmaceutical composition is provided to reduce electrostatic characteristics and adsorption with safety and to improve elution rate and bioavailability. CONSTITUTION: A pharmaceutical composition contains 20-1000 mg of 4-methyl-N-[3-(4-methylimidazole-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyrazine-2-yl-pyrimidine-2-ylamino)-benzamide hydrochloride as an active ingredient and a pharmaceutically acceptable excipient. The pharmaceutical composition is manufactured in the form of a granule, a powder, a tablet, a capsule, or a suspension. A method for manufacturing the pharmaceutical composition comprises the steps of wet/dry-granulating the active ingredient using a solvent or aqueous/oil cosolvent of a surfactant and/or an organic solvent as a solubilizing agent. [Reference numerals] (AA) Dissolution rate (%); (BB) Example 2; (CC) Example 3; (DD) Example 4; (EE) Comparative example 1; (FF) Comparative example 2; (GG) Comparative example 3; (HH) Comparative example 4
Abstract translation: 目的：提供一种药物组合物，以安全降低静电特性和吸附，并提高洗脱速率和生物利用度。 组成：药物组合物含有20-1000mg的4-甲基-N- [3-（4-甲基咪唑-1-基）-5-三氟甲基 - 苯基] -3-（4-吡嗪-2-基 - 嘧啶-2-基） 吡啶-2-基氨基） - 苯甲酰胺盐酸盐作为活性成分和药学上可接受的赋形剂。 药物组合物以颗粒，粉末，片剂，胶囊或悬浮液的形式制造。 制备药物组合物的方法包括使用表面活性剂和/或有机溶剂的溶剂或水/油共溶剂作为增溶剂湿/干造粒活性成分的步骤。 （AA）溶解速度（％） （BB）实施例2; （CC）实施例3; （DD）实施例4 （EE）比较例1; （FF）比较例2; （GG）比较例3; （HH）比较例4
-
Search Results
2
records
(took 0.016 seconds)
